164 related articles for article (PubMed ID: 38130772)
1. Increased Risk of Tooth Loss in Postmenopausal Women With Prevalent Vertebral Fractures: An Observational Study.
Taguchi A; Urano T; Nakamura Y; Shiraki M
JBMR Plus; 2023 Dec; 7(12):e10822. PubMed ID: 38130772
[TBL] [Abstract][Full Text] [Related]
2. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.
Delmas PD; Genant HK; Crans GG; Stock JL; Wong M; Siris E; Adachi JD
Bone; 2003 Oct; 33(4):522-32. PubMed ID: 14555255
[TBL] [Abstract][Full Text] [Related]
3. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Levis S; Theodore G
J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
[TBL] [Abstract][Full Text] [Related]
4. Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos).
Papaioannou A; Joseph L; Ioannidis G; Berger C; Anastassiades T; Brown JP; Hanley DA; Hopman W; Josse RG; Kirkland S; Murray TM; Olszynski WP; Pickard L; Prior JC; Siminoski K; Adachi JD
Osteoporos Int; 2005 May; 16(5):568-78. PubMed ID: 15517191
[TBL] [Abstract][Full Text] [Related]
5. Prevalent vertebral fractures predict subsequent radiographic vertebral fractures in postmenopausal Korean women receiving antiresorptive agent.
Kim SH; Choi HS; Rhee Y; Kim KJ; Lim SK
Osteoporos Int; 2011 Mar; 22(3):781-7. PubMed ID: 20533028
[TBL] [Abstract][Full Text] [Related]
6. The relationship between back pain and future vertebral fracture in postmenopausal women.
Kuroda T; Shiraki M; Tanaka S; Shiraki Y; Narusawa K; Nakamura T
Spine (Phila Pa 1976); 2009 Aug; 34(18):1984-9. PubMed ID: 19680106
[TBL] [Abstract][Full Text] [Related]
7. Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Tanaka S; Saito M; Hagino H; Mori S; Nakamura T; Ohta H; Sone T; Takahashi K; Mitomo Y; Sugimoto T; Soen S;
JBMR Plus; 2022 Oct; 6(10):e10673. PubMed ID: 36248273
[TBL] [Abstract][Full Text] [Related]
8. Microarchitectural abnormalities are more severe in postmenopausal women with vertebral compared to nonvertebral fractures.
Stein EM; Liu XS; Nickolas TL; Cohen A; McMahon DJ; Zhou B; Zhang C; Kamanda-Kosseh M; Cosman F; Nieves J; Guo XE; Shane E
J Clin Endocrinol Metab; 2012 Oct; 97(10):E1918-26. PubMed ID: 22821893
[TBL] [Abstract][Full Text] [Related]
9. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
[TBL] [Abstract][Full Text] [Related]
10. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
Marcus R; Wang O; Satterwhite J; Mitlak B
J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
[TBL] [Abstract][Full Text] [Related]
11. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
12. Relationship between Change in Bone Mineral Density of Lumbar Spine and Risk of New Vertebral and Nonvertebral Fractures: A Meta-Analysis.
Chen L; Liu XP; Zhou B; Guo TY; Yuan F; Abdelrahim MEA; Jiang ZH
Orthop Surg; 2022 Feb; 14(2):199-206. PubMed ID: 34985187
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for vertebral and nonvertebral fracture over 10 years: a population-based study in women.
Finigan J; Greenfield DM; Blumsohn A; Hannon RA; Peel NF; Jiang G; Eastell R
J Bone Miner Res; 2008 Jan; 23(1):75-85. PubMed ID: 17784843
[TBL] [Abstract][Full Text] [Related]
14. Endogenous estradiol and the risk of incident fracture in postmenopausal women: the OPUS study.
Finigan J; Gossiel F; Glüer CC; Felsenberg D; Reid DM; Roux C; Eastell R
Calcif Tissue Int; 2012 Jul; 91(1):59-68. PubMed ID: 22644322
[TBL] [Abstract][Full Text] [Related]
15. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
Harrington JT; Ste-Marie LG; Brandi ML; Civitelli R; Fardellone P; Grauer A; Barton I; Boonen S
Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
[TBL] [Abstract][Full Text] [Related]
16. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
[TBL] [Abstract][Full Text] [Related]
17. Biochemical markers for bone turnover predict risk of vertebral fractures in postmenopausal women over 10 years: the Japanese Population-based Osteoporosis (JPOS) Cohort Study.
Tamaki J; Iki M; Kadowaki E; Sato Y; Chiba Y; Akiba T; Matsumoto T; Nishino H; Kagamimori S; Kagawa Y; Yoneshima H;
Osteoporos Int; 2013 Mar; 24(3):887-97. PubMed ID: 22885773
[TBL] [Abstract][Full Text] [Related]
18. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
Ettinger B; Black DM; Mitlak BH; Knickerbocker RK; Nickelsen T; Genant HK; Christiansen C; Delmas PD; Zanchetta JR; Stakkestad J; Glüer CC; Krueger K; Cohen FJ; Eckert S; Ensrud KE; Avioli LV; Lips P; Cummings SR
JAMA; 1999 Aug; 282(7):637-45. PubMed ID: 10517716
[TBL] [Abstract][Full Text] [Related]
19. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
20. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
